West Pharmaceutical Services (WST) Stock Forecast & Price Target

$370.62 -2.98 (-0.80%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$365.03 -5.59 (-1.51%)

As of 09/25/2026 07:50 PM Eastern

Compare

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
2

Buy
12

Based on 14 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, and 12 have given a buy rating for WST.

Consensus Price Target

$382.00
3.07% Upside

According to the 14 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $382.00. The highest price target for WST is $447.00, while the lowest price target for WST is $295.00. The average price target represents a forecasted upside of 3.07% from the current price of $370.62.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

Type	Current Forecast 9/26/25 to 9/26/26	1 Month Ago 8/27/25 to 8/27/26	3 Months Ago 6/28/25 to 6/28/26	1 Year Ago 9/26/24 to 9/26/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$382.00	$368.08	$340.09	$319.50
Forecasted Upside	3.07% Upside	6.18% Upside	-3.13% Downside	21.96% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

West Pharmaceutical Services Stock vs. The Competition

Type	West Pharmaceutical Services	Healthcare Companies	Broader Market
Consensus Rating Score	2.86	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	3.07% Upside	764.29% Upside	19.21% Upside
News Sentiment Rating	Positive News See Recent WST News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/22/2026	Morgan Stanley 3 of 5 stars	Kallum Titchmarsh Not Rated	Upgrade	Equal Weight ➝ Overweight	$365.00 ➝ $400.00	+10.59%
9/9/2026	UBS Group 4 of 5 stars	Doug Schenkel Not Rated	Boost Target	Buy	$340.00 ➝ $415.00	+22.22%
8/12/2026	Zacks Research 4 of 5 stars		Downgrade	Strong-Buy ➝ Hold
8/7/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C) ➝ Hold (C+)
8/3/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$400.00 ➝ $412.00	+20.81%
7/27/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Markowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$425.00	+28.46%
7/15/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/13/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Curtis Moiles Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$447.00	+26.38%
7/2/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Knight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$350.00 ➝ $390.00	+6.84%
6/9/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$310.00 ➝ $400.00	+25.01%
Get the Latest News and Ratings for WST and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.
6/2/2026	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Etoch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$360.00	+13.97%
6/1/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$375.00	+18.72%
2/13/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Bowers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$315.00	+29.70%
2/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$295.00	+17.85%
9/15/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$311.00	+20.67%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$350.00 ➝ $355.00	+8.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:43 PM ET.

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 25, 2026. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

West Pharmaceutical Services, Inc. recently reported strong financial performance for the quarter ended July 23, 2026, beating consensus estimates with earnings per share of $2.37 compared to the expected $2.08, while revenue of $872.30 million exceeded the forecast of $839.98 million, demonstrating robust demand for its containment and delivery systems.
The company has received a "Moderate Buy" consensus rating from fourteen brokerages, with an average price target of $382.00, which suggests potential upside from the current stock price of $370.62, indicating that analysts believe the stock is undervalued relative to its future earnings potential.
West Pharmaceutical Services, Inc. maintains a strong balance sheet with a low debt-to-equity ratio of 0.07 and a current ratio of 2.82, providing financial stability and the ability to invest in growth initiatives such as its Crystal Zenith cyclic olefin polymer technology and Annex 1 upgrades without significant financial risk.
Institutional investors have shown confidence in the company, with major firms like BlackRock Inc. and State Street Corp adding to their positions in the second quarter of 2026, reflecting a broader trend of institutional accumulation that often signals long-term value recognition in the healthcare equipment sector.
The company's focus on high-growth areas such as biologics exposure and advanced delivery devices positions it to benefit from the increasing complexity of injectable medicines, supporting its guidance for full-year 2026 earnings per share between $8.850 and $9.050, which is above the consensus estimate of $8.610.

West Pharmaceutical Services
Bear Case

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

Recent insider activity shows significant selling, with VP Annette Favorite selling over 15,000 shares in September 2026 alone, including a transaction on September 8, 2026, where she sold 8,135 shares at an average price of $340.81, which may signal reduced internal confidence in the stock's near-term performance.
The stock is trading at a high price-to-earnings ratio of 43.95, which is above the market average, suggesting that the current valuation may not fully account for potential risks or that the stock is priced for perfection, leaving little room for error in future earnings reports.
Short interest has increased slightly, with shares shorted rising to 2,378,099 as of September 15, 2026, representing a 3.40% short percentage of float, indicating that some investors are betting against the stock, which could lead to volatility if the short position is unwound.
West Pharmaceutical Services, Inc. faces operational risks from potential layoffs and cyber disruptions, as noted in recent industry analyses, which could impact its ability to maintain production efficiency and meet the high standards required for pharmaceutical packaging and delivery systems.
The company's dividend yield is low at 0.24%, offering limited income for investors seeking regular cash flow, and the payout ratio of 11.27% suggests that the company is prioritizing reinvestment over shareholder returns, which may not appeal to income-focused investors.

WST Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $382.00, with a high forecast of $447.00 and a low forecast of $295.00.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 3.07% based on their 12-month stock forecasts.

Over the previous 90 days, West Pharmaceutical Services's stock had 2 upgrades and 1 downgrade by analysts.

West Pharmaceutical Services has been rated by research analysts at BNP Paribas Exane, Citigroup, Evercore, KeyCorp, Morgan Stanley, TD Cowen, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like West Pharmaceutical Services more than other "healthcare" companies. The consensus rating for West Pharmaceutical Services is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how WST compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With West Pharmaceutical Services Recommendations

MarketBeat monitors more than a dozen sources for West Pharmaceutical Services analyst ratings, with the most recent rating issued on 9/22/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

West Pharmaceutical Services (WST) Stock Forecast & Price Target